Synonyms: PD 0325901 | PD-0325901 | PD0325901
Compound class:
Synthetic organic
Comment: Mirdametinib (PD 0325901) is a selective and non ATP-competitive MEK inhibitor [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Mirdametinib (PD 0325901) is being assessed in Phase 2 clinical trials for advanced KRAS mutant colorectal cancer (in combination with dacomitinib; NCT02039336), KRAS mutant non-small cell lung cancer (in combination with palbociclib; NCT02022982) and neurofibromatosis type 1 (NCT02096471). Trials for non-small-cell lung cancer and melanoma, colonic neoplasms and breast cancer have been terminated. |